Items tagged with Treatment
WHO interim guidance on the use of delamanid in the treatment of MDR-TB (post with simple image)
The guidance lists five conditions that must be in place if delamanid is used to treat adults with MDR-TB.
“You see yourself vanishing and you think: I’m going to die” (post with simple image)
Andaleeb Rinquest remembers the moment she accepted, with certainty, the imminence of her own death.
Drug-resistant tuberculosis patients face dwindling treatment options (post with simple image)
Doctors believe there is greater drug resistance and complexity of TB, which disproportionally affects immigrants.
Latent TB: Shorter course of therapy effective in children (post with simple image)
In children with latent tuberculosis, 3 months of combined therapy with isoniazid and rifapentine is safe and as effective as 9 months of isoniazid alone.
Drug-resistant tuberculosis a tiny — but potent — foe in L.A. County (post with simple image)
Otsuka rejected Dr. Caitlin Reed’s attempt to obtain delamanid for her patient, Gary, who has the most drug-resistant case of TB ever identified in the United States.
Inside India: The deadly effects of red tape (post with simple image)
Red tape and over-regulation can kill.
Zimbabwe faces troubling spike in cases of multidrug-resistant TB (post with simple image)
- About eight years ago, 44-year-old Tilda Chihota was struck with tuberculosis which kept her bed-ridden for over six months at her rural home in Zimbabwe’s Mwenezi district, 144 kilometres southwest of Masvingo, the country’s oldest town.
Phase 2a published results show the potential of a new TB regimen with novel drugs bedaquiline and pretomanid (PA-824) (post with simple image)
Results of study testing BPaZ published in American Journal of Respiratory and Critical Care Medicine; Regimen now being tested in Phase 2b clinical trial
TB Alliance advances next-generation TB drug candidate into clinical testing (post with simple image)
TBA-354 is the first potential tuberculosis drug to advance to Phase 1 trial in six years.
Stop TB Partnership's Global Drug Facility (GDF) achieves historic price reduction for MDR-TB drug Cycloserine (post with simple image)
This price reduction is expected to save up to USD 22 million annually, enabling treatment for more people living with MDR-TB.
Page 87 of 105 · Total posts: 0
←First 86 87 88 Last→